Amylyx Pharmaceuticals, Inc. (AMLX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 21.15M USD | Liabilities, Current |
| Cash and equivalents | 49.33M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 201.43M USD | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $21.15M | $49.33M | $201.43M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $15.97M | $229.14M | $50.63M | (m) | (m) | (m) |
| 2025-12-31 | $317.07M | $22.69M | $226.65M | $90.33M | $88.00K | (m) | 13.98× |
| 2025-09-30 | $344.12M | $25.79M | $225.18M | $118.81M | $132.00K | (m) | 13.34× |
| 2025-06-30 | $180.93M | $21.42M | $58.09M | $122.74M | $103.00K | (m) | 8.45× |
| 2025-03-31 | $204.37M | $17.93M | $59.76M | $144.30M | $300.00K | (m) | 11.40× |
| 2024-12-31 | $176.95M | $28.41M | $77.39M | $99.11M | $447.00K | (m) | 6.23× |
| 2024-09-30 | $236.13M | $53.91M | $71.84M | $162.56M | $1.73M | (m) | 4.38× |
| 2024-06-30 | (m) | $70.08M | $75.00M | (m) | $4.09M | (m) | (m) |
| 2024-03-31 | (m) | $91.64M | $170.55M | (m) | $20.35M | (m) | (m) |
| 2023-12-31 | (m) | $82.04M | $170.20M | (m) | $40.05M | $38.32M | (m) |
| 2023-09-30 | (m) | $45.62M | $135.26M | (m) | $29.35M | $32.37M | (m) |
| 2023-06-30 | (m) | $64.08M | $247.76M | (m) | $33.47M | $24.86M | (m) |
| 2023-03-31 | (m) | $51.62M | $114.56M | (m) | $17.55M | $13.07M | (m) |
| 2022-12-31 | (m) | $46.61M | $62.53M | (m) | $15.31M | $9.77M | (m) |
| 2022-09-30 | (m) | $32.65M | $107.73M | (m) | $137.00K | $563.00K | (m) |
| 2022-06-30 | (m) | $27.16M | $67.44M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $27.71M | $110.40M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $17.40M | $50.19M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |